$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Can tucatinib/tucatinib completely prevent breast cancer metastasis?
2026-02-01 22:25:32
Check Details
What is tucatinib/tucatinib?
2026-02-01 22:25:32
Check Details
The HER2 CLIMB-02 trial of tucatinib/tucatinib in HER2+ breast cancer
2026-02-01 22:25:32
Check Details
Osimertinib (Tagressa) belongs to the first generation of targeted therapy drugs
2026-02-01 22:25:32
Check Details
Osimertinib (Tagressa) medical insurance price in 2024
2026-02-01 22:25:32
Check Details
The latest purchase price of osimertinib (Tagressa) in 2024
2026-02-01 22:25:32
Check Details
Osimertinib (Tagressa) medical insurance reimbursement conditions
2026-02-01 22:25:32
Check Details
The latest medical insurance reimbursement policy for osimertinib (Tagressa) in 2024
2026-02-01 22:25:32
Check Details
Where to buy Osimertinib (Tagressa) and where to buy it
2026-02-01 22:25:32
Check Details
What are the side effects of Osimertinib (Tagressa)? How to deal with side effects?
2026-02-01 22:25:32
Check Details
Patient instructions for the targeted drug osimertinib mesylate (Tagrisso) for the treatment of lung cancer
2026-02-01 22:25:32
Check Details
Usage, dosage and best time of taking osimertinib mesylate (Tagressa)
2026-02-01 22:25:32
Check Details
1
2
...
675
676
677
678
679
680
681
...
10222
10223
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
FDA Approves Lytenava: First Ophthalmic Bevacizumab for Wet AMD
2
Simtriyo (Centanafadine): World's First NDSRI ADHD Drug Approved by FDA
3
Lipfendra (Enlicitide): The World's First Oral PCSK9 Inhibitor Approved by FDA
4
Orforglipron: The World's First Oral Small-Molecule GLP-1 Receptor Agonist for Weight Management
5
Cabozantinib Capsules: A Multi-Targeted Therapy for Progressive Medullary Thyroid Cancer
6
Lorlatinib: Mechanism, Advantages, and Key Considerations of Third-Generation ALK Inhibitor Therapy in ALK-Positive NSCLC
7
FDA Approves Subcutaneous Isatuximab (Sarclisa) for Multiple Myeloma: A New Administration Option
8
Pemigatinib Side Effects Explained: Managing Adverse Reactions of FGFR-Targeted Therapy in Cholangiocarcinoma
9
Selpercatinib: Before or After Meals? A Complete Guide to RET-Targeted Therapy Administration
10
Mitotane for Adrenocortical Carcinoma: Dosing Guidelines and Therapeutic Drug Monitoring
11
Vadadustat: Clinical Evidence and Patient Benefits of an Oral HIF-PHI for CKD-Related Anemia
12
Ponatinib vs. Olverembatinib: A Multidimensional Comparison of Third-Generation BCR-ABL Inhibitors